C.R. Bard downgraded to Sell from Underperform at CLSA CLSA downgraded CR Bard based on concerns its risk profile has increased with its new multi-year-plan following disappointing guidance. Price target lowered to $96 from $98.
C.R. Bard upgraded to Buy from Underperform at BofA/Merrill BofA/Merrill upgraded C.R. Bard two notches to Buy from Underperform and increased its price target to $200 following Q1 results. The firm sees upside to Bard's drug eluting balloon franchise following the report and recent survey results, and expects the company to utilize its under leverage balance sheet in 2015.